Use of a Benchmark Tracking Assessment to Support Expansion of Buprenorphine for Treatment of Opioid Use Disorder in Primary Care

被引:2
|
作者
Sussman, Andrew L. [1 ,2 ]
Crawford, Jennifer N. [3 ]
Brakey, Heidi Rishel [4 ]
Alkhafaji, Rana S. [3 ]
Myers, Orrin B. [1 ]
Jacobsohn, Vanessa [3 ]
Bhatt, Snehal [3 ]
Salvador, Julie [3 ]
机构
[1] Univ New Mexico, Dept Family & Community Med, Hlth Sci Ctr, Albuquerque, NM 87131 USA
[2] Univ New Mexico, Comprehens Canc Ctr, Hlth Sci Ctr, Albuquerque, NM 87131 USA
[3] Univ New Mexico, Hlth Sci Ctr, Dept Psychiat & Behav Sci, Albuquerque, NM 87131 USA
[4] Univ New Mexico, Clin & Translat Sci Ctr, Hlth Sci Ctr, Albuquerque, NM 87131 USA
基金
美国医疗保健研究与质量局;
关键词
Access to Health Care; Benchmarking; Buprenorphine; Extensions for Community Healthcare Outcomes (ECHO); Internet-Based Intervention; Medication-Assisted Treatment of Opioid; Opioid-Related Disorders; Opioids; Primary Health Care; PHYSICIANS; BARRIERS;
D O I
10.3122/jabfm.2021.06.210111
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Introduction: Barriers to the expansion of opioid use disorder (OUD) treatment in primary care using buprenorphine are well documented. Providers require support along a continuum. A systematic tracking framework to enhance provider progress along this continuum is lacking. Methods: We developed a benchmark tracking assessment (BTA) as part of data collection in a 5-year study to examine the impact of provider participation in an online intervention to support expansion of buprenorphine treatment for OUD in rural primary care. Providers were contacted via phone every 3 months for up to 2 years to track their advancement along the 5 identified key benchmarks and were offered support for any barriers encountered. Results: Forty-one providers enrolled in the study. Almost half (49%) did not experience a barrier that prevented them from accomplishing their next benchmark. Of the remaining 51% of providers, the majority (75%) experienced barriers early in the training and licensure phases, with most citing lack of time as the main reason. Conclusion: The BTA offers a feasible approach to identifying challenges along the training to prescription continuum and facilitated targeted support to address barriers. This framework has the potential, with locally contextual adaptations, to guide medication-assisted treatment implementation and training efforts. ( J Am Board Fam Med 2021;34:1216-1220.)
引用
收藏
页码:1216 / 1220
页数:5
相关论文
共 50 条
  • [41] Patients' Perspectives on Discontinuing Buprenorphine for the Treatment of Opioid Use Disorder
    Wyse, Jessica J.
    Eckhardt, Alison
    Waller, Dylan
    Gordon, Adam J.
    Shull, Sarah
    Lovejoy, Travis I.
    Mackey, Katherine
    Morasco, Benjamin J.
    [J]. JOURNAL OF ADDICTION MEDICINE, 2024, 18 (03) : 300 - 305
  • [42] Home Induction of Buprenorphine for Treatment of Opioid Use Disorder in Pregnancy
    Kelly, Jeannie C.
    Raghuraman, Nandini
    Stout, Molly J.
    Russell, Sharman
    Perez, Marta
    Nazeer, Sarah
    El Helou, Nicole
    Zhang, Fan
    Carter, Ebony
    [J]. OBSTETRICS AND GYNECOLOGY, 2021, 138 (04): : 655 - 659
  • [43] PREHOSPITAL INITIATION OF BUPRENORPHINE TREATMENT FOR OPIOID USE DISORDER BY PARAMEDICS
    Hern, H. Gene
    Goldstein, David
    Kalmin, M.
    Kidane, S.
    Shoptaw, S.
    Tzvieli, Ori
    Herring, Andrew A.
    [J]. PREHOSPITAL EMERGENCY CARE, 2022, 26 (06) : 811 - 817
  • [44] THE DILEMMA OF ENDING BUPRENORPHINE TREATMENT IN YOUTH WITH OPIOID USE DISORDER
    Kumar, Nihit
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY, 2021, 60 (10): : S98 - S98
  • [45] Barriers and facilitators to nurse practitioner buprenorphine prescribing for opioid use disorder in primary care settings
    Speight, Chandra
    Caiola, Courtney
    Tyndall, Deborah E.
    Scott, Elaine S.
    [J]. JOURNAL OF THE AMERICAN ASSOCIATION OF NURSE PRACTITIONERS, 2023, 35 (02) : 112 - 121
  • [46] Buprenorphine Receipt and Retention for Opioid Use Disorder Following an Initiative to Increase Access in Primary Care
    Hawkins, Eric J.
    Malte, Carol A.
    Hagedorn, Hildi J.
    Gordon, Adam J.
    Williams, Emily C.
    Trim, Ryan S.
    Blanchard, Brittany E.
    Lott, Aline
    Danner, Anissa N.
    Saxon, Andrew J.
    [J]. JOURNAL OF ADDICTION MEDICINE, 2024, 18 (03) : 240 - 247
  • [47] Pharmacy Availability of Buprenorphine for Opioid Use Disorder Treatment in the US
    Weiner, Scott G.
    Qato, Dima M.
    Faust, Jeremy Samuel
    Clear, Brian
    [J]. JAMA NETWORK OPEN, 2023, 6 (05) : E2316089
  • [48] Exploratory Economic Evaluation of Buprenorphine Treatment in opioid Use Disorder
    Elarabi, Hesham Farouk
    Al Ghaferi, Hamad
    Hasan, Nael
    Lee, Amanda J.
    Shawky, Mansour
    Al Kathiri, Helal
    Elrasheed, Abuelgasim
    Al Maamari, Samya
    Gawad, Tarek A.
    Radwan, Doaa
    Adem, Abdu
    Marsden, John
    [J]. JOURNAL OF MENTAL HEALTH POLICY AND ECONOMICS, 2021, 24 (03): : 89 - 95
  • [49] Buprenorphine treatment services for opioid use disorder in rural areas
    Lopes, John E., Jr.
    [J]. JAAPA-JOURNAL OF THE AMERICAN ACADEMY OF PHYSICIAN ASSISTANTS, 2019, 32 (07):
  • [50] New buprenorphine treatment option approved for opioid use disorder
    不详
    [J]. NURSE PRACTITIONER, 2023, 48 (08): : 48 - 48